Abstract
The formation of granuloma is one of the characteristic features of tuberculosis. Besides, rise in the concentration of serum amyloid A (SAA) protein is the indicator for chronic inflammation associated with tuberculosis. The predisposition of SAA driven secondary amyloidosis in tuberculosis is well documented. However, SAA derived amyloid onset and deposition start sites are not well chracterised in tuberculosis and other chronic inflammatory conditions. We hypothesized that granuloma could be a potential site for amyloid deposition because of the presence of SAA protein and proteases that cleave SAA into aggregation prone fragments. 150 tuberculosis patients were screened and biopsies were collected from the affected organs of these patients. 20 patients showed eosinophilic hyaline rich deposits within and surrounding granuloma respectively. They were further screened for the presence of amyloid deposits. The hyaline material, upon Congo red staining exhibited characteristic apple green birefringence under polarized light, confirming deposition of amyloid. Further upon immuno histochemical staining with anti-SAA antibody, the amyloid enriched areas showed positive immunoreactivity. In this pilot study, wexx have shown granuloma as a potential site for serum amyloid A derived amyloid deposition in tuberculosis patients. This study would set a stage to expxand the clinical and fundamental research for understanding the mechanism of amyloid formation in granuloma underlying tuberculosis and other chronic inflammatory conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Not applicable
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GSVM Medical College Ethics committee Approval:Yes Indian Institute of Technology Kanpur Approval: Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author order: updated Author affiliation: updated Results and Discussion: updated Methods (Thioflavin T staining) : updated Figures 1,2: modified and updated Figure 3: added
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- TB
- tuberculosis
- WHO
- world health organization
- FDA
- Food and Drug Administration
- SAA
- serum amyloid A
- H&E
- Hematoxylin and eosin
- FFPE
- formalin fixed paraffin embedded
- CR
- Congo red
- MMPs
- matrix metalloproteinases
- mM
- milli molar
- Mtb
- Mycobacterium tuberculosis
- SD
- standard deviation
